Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 288

1.

Artificial Intelligence With Deep Learning Technology Looks Into Diabetic Retinopathy Screening.

Wong TY, Bressler NM.

JAMA. 2016 Nov 29. doi: 10.1001/jama.2016.17563. [Epub ahead of print] No abstract available.

PMID:
27898977
2.

Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy.

Kimel M, Leidy NK, Tschosik E, Dolan C, Souied EH, Varma R, Bressler NM.

Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6298-6304. doi: 10.1167/iovs.16-20361.

PMID:
27893095
3.

Announcing the New JAMAOphthalmology.com.

Gee P, Kelly C, Berkwits M, Bressler NM.

JAMA Ophthalmol. 2016 Oct 10. doi: 10.1001/jamaophthalmol.2016.4331. [Epub ahead of print] No abstract available.

PMID:
27723865
4.

Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.

Jampol LM, Glassman AR, Bressler NM, Wells JA, Ayala AR; Diabetic Retinopathy Clinical Research Network..

JAMA Ophthalmol. 2016 Oct 6. doi: 10.1001/jamaophthalmol.2016.3698. [Epub ahead of print]

PMID:
27711918
5.
6.

Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial.

Beaulieu WT, Bressler NM, Melia M, Owsley C, Mein CE, Gross JG, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network..

Am J Ophthalmol. 2016 Oct;170:206-213. doi: 10.1016/j.ajo.2016.08.008.

PMID:
27523491
7.

Public Attitudes About Eye and Vision Health.

Scott AW, Bressler NM, Ffolkes S, Wittenborn JS, Jorkasky J.

JAMA Ophthalmol. 2016 Oct 1;134(10):1111-1118. doi: 10.1001/jamaophthalmol.2016.2627.

PMID:
27490785
8.

Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.

Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR; Diabetic Retinopathy Clinical Research Network..

JAMA Ophthalmol. 2016 Aug 1;134(8):888-96. doi: 10.1001/jamaophthalmol.2016.1669.

PMID:
27280850
9.

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network..

Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022.

PMID:
26935357
10.

Recent approaches to evaluating and monitoring geographic atrophy.

Chaikitmongkol V, Tadarati M, Bressler NM.

Curr Opin Ophthalmol. 2016 May;27(3):217-23. doi: 10.1097/ICU.0000000000000259. Review.

PMID:
26866953
11.

Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema.

Bressler SB, Glassman AR, Almukhtar T, Bressler NM, Ferris FL, Googe JM Jr, Gupta SK, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network..

Am J Ophthalmol. 2016 Apr;164:57-68. doi: 10.1016/j.ajo.2015.12.025.

PMID:
26802783
12.

Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.

Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network..

JAMA Ophthalmol. 2016 Mar;134(3):278-85. doi: 10.1001/jamaophthalmol.2015.5346.

PMID:
26746868
13.

Comparison of Prevalence of Diabetic Macular Edema Based on Monocular Fundus Photography vs Optical Coherence Tomography.

Wang YT, Tadarati M, Wolfson Y, Bressler SB, Bressler NM.

JAMA Ophthalmol. 2016 Feb;134(2):222-8. doi: 10.1001/jamaophthalmol.2015.5332.

PMID:
26719967
14.

The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8.

AREDS2 Research Group., Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY.

Ophthalmology. 2016 Apr;123(4):916-7. doi: 10.1016/j.ophtha.2015.10.040. No abstract available.

PMID:
26686966
15.

Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network..

JAMA Ophthalmol. 2016 Feb;134(2):127-34. doi: 10.1001/jamaophthalmol.2015.4599. Erratum in: JAMA Ophthalmol. 2016 Apr;134(4):469.

PMID:
26605836
16.

Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials.

Bressler NM, Varma R, Mitchell P, Suñer IJ, Dolan C, Ward J, Ferreira A, Ehrlich JS, Turpcu A.

JAMA Ophthalmol. 2016 Feb;134(2):160-6. doi: 10.1001/jamaophthalmol.2015.4636.

PMID:
26584450
17.

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Writing Committee for the Diabetic Retinopathy Clinical Research Network., Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW.

JAMA. 2015 Nov 24;314(20):2137-46. doi: 10.1001/jama.2015.15217. Erratum in: JAMA. 2016 Mar 1;315(9):944.

PMID:
26565927
18.

Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.

Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel..

JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.

PMID:
26512939
19.

Qualifying to Use a Home Monitoring Device for Detection of Neovascular Age-Related Macular Degeneration.

Thomas M, Wolfson Y, Zayit-Soudry S, Bressler SB, Bressler NM.

JAMA Ophthalmol. 2015 Dec;133(12):1425-30. doi: 10.1001/jamaophthalmol.2015.3684.

PMID:
26468999
20.

RECURRENCE OF VITELLIFORM LESIONS ASSOCIATED WITH TEMPORARY VISION LOSS IN BEST VITELLIFORM MACULAR DYSTROPHY.

Wang YT, Tadarati M, Scholl HP, Bressler NM.

Retin Cases Brief Rep. 2016 Winter;10(1):63-71. doi: 10.1097/ICB.0000000000000207.

PMID:
26418331
Items per page

Supplemental Content

Loading ...
Support Center